4.8 Article

Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells

期刊

BIOMATERIALS
卷 34, 期 16, 页码 4098-4108

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.02.034

关键词

Paclitaxel; PHBV; Nanoparticle; Ovarian cancer; Drug delivery; Molecular dynamics simulations

资金

  1. Centro para el Desarrollo de la Nanociencia y Nanotecnologia (CEDENNA) [FB0807]
  2. Biomedical Research Consortium of Chile [CTU06]
  3. Fondo Nacional de Desarrollo Cientifico y Tecnologico Gobierno de Chile (FONDECYT) [1120712, 1080163, 1100870, 3120003]

向作者/读者索取更多资源

This report is an integrated study to include the molecular simulation, physicochemical characterization and biological analysis of a paclitaxel-loaded PHBV nanoparticle that demonstrates uptake, release and cytotoxicity in cancer cell lines. Taking this nanoparticle one step closer to its use in a clinical setting, we demonstrate that it causes significant cell death in primary cultures of stage IIIc serous ovarian cancer cells isolated from six patients. Molecular simulations revealed a high affinity of paclitaxel for the water-polymer interface, thus the drug is delivered only when the polymer near it is degraded. The Fourier transform infrared spectroscopy suggests the formation of a short-lived crystalline phase, also observed in the CG simulations, and transmission electron microscopy revealed branched structures on the surface of particles, which disappeared after 4 days. Biological analyses indicated that these particles have a 48-h window of toxicity protection, allowing for the endocytosis of the particle by the cells; this finding was corroborated by confocal microscopy and flow cytometry. The low cost to synthesize PHBV using microorganisms and the potential chemical modifications of the polymer make it attractive for inexpensive, large-scale pharmaceutical production. (c) 2013 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据